Trial · NCT00274716
Results by group52
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 52
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 in Participants With Higher Body Mass Indices (BMI) | MK-0736 2.0 mg High BMI | -4.2 | Standard Deviation 7.3 | mm Hg | |
| Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 in Participants With Higher Body Mass Indices (BMI) | MK-0736 7.0 mg High BMI | -2.4 | Standard Deviation 8.1 | mm Hg | |
| Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 in Participants With Higher Body Mass Indices (BMI) | MK-0916 6.0 mg High BMI | -3.1 | Standard Deviation 7.9 | mm Hg | |
| Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 in Participants With Higher Body Mass Indices (BMI) | Placebo High BMI | -0.2 | Standard Deviation 8.7 | mm Hg | |
| Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12 in Participants With Higher Body Mass Indices (BMI) | MK-0736 2.0 mg High BMI | -3.5 | Standard Deviation 13.2 | mm Hg | |
| Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12 in Participants With Higher Body Mass Indices (BMI) | MK-0736 7.0 mg High BMI | -4.2 | Standard Deviation 12.9 | mm Hg | |
| Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12 in Participants With Higher Body Mass Indices (BMI) | MK-0916 6.0 mg High BMI | -3.2 | Standard Deviation 11.3 | mm Hg | |
| Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12 in Participants With Higher Body Mass Indices (BMI) | Placebo High BMI | 0.7 | Standard Deviation 12.2 | mm Hg | |
| Change From Baseline in Body Weight (kg) at Week 12 in Participants With Higher BMI | MK-0736 2.0 mg High BMI | -0.6 | Standard Deviation 1.8 | kg | |
| Change From Baseline in Body Weight (kg) at Week 12 in Participants With Higher BMI | MK-0736 7.0 mg High BMI | -0.9 | Standard Deviation 2.0 | kg | |
| Change From Baseline in Body Weight (kg) at Week 12 in Participants With Higher BMI | MK-0916 6.0 mg High BMI | -1.2 | Standard Deviation 1.8 | kg | |
| Change From Baseline in Body Weight (kg) at Week 12 in Participants With Higher BMI | Placebo High BMI | 0.5 | Standard Deviation 1.9 | kg | |
| Change From Baseline in Waist Circumference at Week 12 in Participants With Higher BMI | MK-0736 2.0 mg High BMI | -1.9 | Standard Deviation 4.9 | cm | |
| Change From Baseline in Waist Circumference at Week 12 in Participants With Higher BMI | MK-0736 7.0 mg High BMI | -0.9 | Standard Deviation 2.9 | cm | |
| Change From Baseline in Waist Circumference at Week 12 in Participants With Higher BMI | MK-0916 6.0 mg High BMI | -0.3 | Standard Deviation 4.9 | cm | |
| Change From Baseline in Waist Circumference at Week 12 in Participants With Higher BMI | Placebo High BMI | 1.2 | Standard Deviation 6.1 | cm | |
| Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 in Participants With Higher Body Mass Indices (BMI) | MK-0736 2.0 mg High BMI | -1.0 | Standard Deviation 23.3 | percentage change | |
| Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 in Participants With Higher Body Mass Indices (BMI) | MK-0736 7.0 mg High BMI | -5.2 | Standard Deviation 20.4 | percentage change | |
| Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 in Participants With Higher Body Mass Indices (BMI) | MK-0916 6.0 mg High BMI | 4.5 | Standard Deviation 23.0 | percentage change | |
| Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 in Participants With Higher Body Mass Indices (BMI) | Placebo High BMI | 5.7 | Standard Deviation 30.8 | percentage change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00274716/results